MET and non-small cell lung carcinoma: In a female patient diagnosed with NSCLC with MET exon 14 skipping mutation and with brain metastases, and having received WBRT, remarkable clinical improvement was achieved after a 1-month treatment with tepotinib (500 mg/die).